Wedbush Reaffirms Outperform Rating for Jade Biosciences (NASDAQ:JBIO)

Key Points

• Wedbush reiterated an Outperform rating on Jade Biosciences (JBIO) with a $24 price objective, implying roughly a 70.8% upside from the current stock price.
• Analyst coverage is mixed but tilted positive: MarketBeat shows a consensus of Moderate Buy with a $25 consensus price target (one Strong Buy, five Buy, one Sell).
• Jade is a clinical‑stage dermatology biotech (market cap ≈ $693M) that recently reported an EPS beat of −$0.11 vs. −$0.45 consensus.

Jade Biosciences (NASDAQ:JBIO - Get Free Report)'s stock had its "outperform" rating reiterated by Wedbush in a research note issued on Monday,Benzinga reports. They currently have a $24.00 price objective on the stock. Wedbush's price objective suggests a potential upside of 70.82% from the stock's current price.

Other research analysts also recently issued reports about the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Jade Biosciences in a report on Monday, December 29th. Stifel Nicolaus set a $40.00 price objective on shares of Jade Biosciences in a research note on Friday. Wall Street Zen raised shares of Jade Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, November 15th. Lifesci Capital upgraded shares of Jade Biosciences to a "strong-buy" rating in a research note on Friday. Finally, HC Wainwright initiated coverage on shares of Jade Biosciences in a research report on Wednesday, January 7th. They set a "buy" rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $25.00.

Jade Biosciences Stock Performance

Shares of JBIO opened at $14.05 on Monday. The business's 50-day moving average is $14.78 and its two-hundred day moving average is $11.95. The company has a market capitalization of $692.81 million, a P/E ratio of -3.05 and a beta of 1.03. Jade Biosciences has a fifty-two week low of $6.57 and a fifty-two week high of $100.10.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last issued its quarterly earnings data on Friday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.34.

Institutional Investors Weigh In On Jade Biosciences

A number of institutional investors have recently added to or reduced their stakes in JBIO. California State Teachers Retirement System increased its stake in shares of Jade Biosciences by 40.3% during the fourth quarter. California State Teachers Retirement System now owns 2,850 shares of the company's stock worth $44,000 after purchasing an additional 819 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Jade Biosciences by 40.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,422 shares of the company's stock worth $38,000 after buying an additional 1,279 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its stake in Jade Biosciences by 16.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 12,097 shares of the company's stock worth $187,000 after buying an additional 1,709 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Jade Biosciences by 26.6% in the 4th quarter. The Manufacturers Life Insurance Company now owns 14,012 shares of the company's stock valued at $216,000 after purchasing an additional 2,940 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of Jade Biosciences in the second quarter valued at about $29,000.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.